Yixin Pfister-Fu
Yixin Pfister-Fu has worked on the following 11 EPO patent applications which have been published in the last five years:
EP13701194
NEW FORMS AND SALTS OF A DIHYDROPYRROLO[1,2-C]IMIDAZOLYL ALDOSTERONE SYNTHASE OR AROMATASE INHIBITOR
- IPC classification:
- A61K 31/407, A61P 5/38, C07D 487/04
- Applicant:
- Novartis AG
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ NO OPPOSITION FILED WITHIN TIMELIMIT
EP13712589
FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS
- IPC classification:
- A61K 31/506, A61P 19/08
- Applicant:
- Novartis AG
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ EXAMINATION IN PROGRESS
EP13718671
TYROSINE KINASE INHIBITOR COMBINATIONS AND THEIR USE
- IPC classification:
- A61K 31/5025, A61K 31/506, A61K 31/53, A61K 45/06
- Applicant:
- Novartis AG
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ GRANT OF PATENT INTENDED
EP13720275
COMBINATION OF SOMATOSTATIN-ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS
- IPC classification:
- A61K 31/4164, A61K 38/31, A61P 5/00
- Applicant:
- Novartis AG
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ EXAMINATION IN PROGRESS
EP15155712
Antibody formulations
- IPC classification:
- A61K 9/00, A61K 39/395, C07K 16/00, C07K 16/28
- Applicant:
- Novartis AG
- Applicant:
- GlaxoSmithKline LLC
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Agent:
- Alastair George Sayce, GlaxoSmithKline
- Status:
- █ EXAMINATION IN PROGRESS
EP12891015
PRESSURE RESPONSIVE DOWNHOLE TOOL HAVING A SELECTIVELY ACTIVATABLE PRESSURE RELIEF VALVE AND RELATED METHODS
- IPC classification:
- E21B 34/06, E21B 34/08
- Applicant:
- Halliburton Energy Services, Inc.
- Agent:
- Hoffmann Eitle PartmbB
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ GRANT OF PATENT INTENDED
EP12734212
NOVEL USES
- IPC classification:
- A61K 39/395
- Applicant:
- Novartis AG
- Applicant:
- GlaxoSmithKline Intellectual Property Development Limited
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Agent:
- Alastair George Sayce, GlaxoSmithKline
- Status:
- █ EXAMINATION IN PROGRESS
EP13857873
NOVEL PHARMACEUTICAL COMPOSITION
- IPC classification:
- A61K 9/14, A61K 31/519, A61P 35/00
- Applicant:
- Novartis AG
- Applicant:
- GlaxoSmithKline LLC
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ EXAMINATION REQUESTED
EP13858515
COMBINATION
- IPC classification:
- A61K 9/20, A61P 35/00, C07D 231/38
- Applicant:
- GlaxoSmithKline LLC
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ GRANT OF PATENT INTENDED
EP14730592
COMBINATION THERAPY CONTAINING A PI3K-ALPHA INHIBITOR AND FGFR KINASE INHIBITOR FOR TREATING CANCER
- IPC classification:
- A61K 31/4439, A61K 31/506, A61K 45/06, A61P 35/00
- Applicant:
- Novartis AG
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ APPLICATION WITHDRAWN
EP14819084
PHARMACEUTICAL DOSAGE FORMS
- IPC classification:
- A61K 9/16, A61K 9/48, A61K 31/506
- Applicant:
- Novartis AG
- Agent:
- Yixin Pfister-Fu, Novartis Pharma AG
- Status:
- █ EXAMINATION REQUESTED